Brief: BioCryst Pharmaceuticals Q4 EPS USD -0.31
26/02/2024 12:00
Feb 26 (Reuters) - BioCryst Pharmaceuticals Q4 operating expenses USD 136.071 million. * Q4 net income USD -61.731 million * Q4 pretax profit USD -63.162 million * Q4 operating income USD -42.67 million
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026